Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 20 (12), 1655-1669, 2019-12
Elsevier BV